LabGenomics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
LabGenomics provides genetic diagnostic testing services, most notably a non-invasive prenatal screening test that checks a mother's blood sample for chromosomal abnormalities in the fetus, avoiding the risks of traditional needle-based procedures.
Its tests are used by expectant mothers and newborns, delivered through a network spanning thousands of medical institutions and specialist obstetrics clinics across South Korea. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core product line is its 'MomGuard' prenatal test suite, which ranges from a standard tier to a premium tier capable of screening for a broad range of chromosomal conditions.
Summary is AI-generated and may contain errors · figures from DART filings
The company's genetic test items are registered with Korea's Korea Disease Control and Prevention Agency, a regulatory requirement that governs which tests may be commercially offered domestically.
LabGenomics in five facts
What does LabGenomics do?
LabGenomics provides genetic diagnostic testing services, most notably a non-invasive prenatal screening test that checks a mother's blood sample for chromosomal abnormalities in the fetus, avoiding the risks of traditional needle-based procedures.
Where is LabGenomics listed and in which sector?
LabGenomics (Korean name: 랩지노믹스) trades under KRX code 084650 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is LabGenomics?
Its market capitalisation was US$25.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were LabGenomics's latest annual revenue and operating profit?
For fiscal year 2025, LabGenomics reported revenue of US$66.5M, an operating loss of US$40.4M and a net loss of US$48.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 2.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 30
- Report on securities held by executives/major shareholdersSep 30
- Report on securities held by executives/major shareholdersSep 30
- Report on securities held by executives/major shareholdersSep 30
- Report on large shareholdings (5% rule) (standard)Sep 30
- Trading suspension liftedSep 22
- Trading suspension (share consolidation/split registration)
Trading in LabGenomics Co., Ltd. common shares will be suspended from September 1, 2026 through the day before the relisting of the new share certificates, pursuant to KOSDAQ market rules, due to a share consolidation.
M&A · Aug 27 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 18
- Material event report (convertible bonds)
LabGenomics disclosed convertible bonds to raise US$13.4M, about 50.5% of its market value.
Capital raise · May 13 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
LabGenomics reported consolidated results for FY2025: revenue of US$61.6M (+2.6% year on year), an operating loss of US$22.7M and a net loss of US$25.7M.
Earnings · Feb 27